二甲双胍在糖尿病预防长期随访中的效果评估:随机试验中的治疗偏离分析
本研究基于糖尿病预防计划(DPP)及其长期随访DPPOS,采用统计方法处理治疗偏离,评估二甲双胍对糖尿病及并发症的长期效果。结果显示二甲双胍持续降低糖尿病发病率,但对糖尿病确诊后并发症的获益未显著改变意向性分析结论,所有分析方法的风险比95%CI均包含1.0(糖尿病发病率除外)。
要点
- 二甲双胍持续降低高危成人糖尿病发病率。
- 治疗偏离主要因HbA1c≥7.0%后由临床医生调整治疗。
- 除糖尿病发病率外,其他结局的风险比95%CI均包含1.0。
核心结论
- 二甲双胍持续降低糖尿病发病率,但对糖尿病确诊后并发症的长期获益证据不足。
研究设计与样本
- DPP为3年随机临床试验,比较生活方式和二甲双胍与安慰剂在高危成人中的糖尿病预防效果。
- DPPOS为长期随访研究,评估22年间糖尿病及并发症进展。
- 采用统计方法估计干预效果,处理治疗偏离。
主要发现
- 二甲双胍持续降低糖尿病发病率。
- 评估二甲双胍对糖尿病确诊后并发症的获益未显著改变意向性分析结论。
- 所有分析方法的风险比95%CI均包含1.0(无效应),糖尿病发病率除外。
临床怎么用
- 二甲双胍可用于高危成人糖尿病预防,但对其长期并发症的额外获益需进一步研究。
局限性
- 治疗偏离(如糖尿病确诊后调整治疗)使长期效果评估复杂。
- 阐明二甲双胍在糖尿病预防之外减轻并发症的长期作用具有挑战性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Diabetes Prevention Program (DPP) was a 3-year randomized clinical trial (RCT) with evaluation of lifestyle and metformin interventions compared with placebo for diabetes prevention in high-risk adults. Both interventions significantly reduced diabetes incidence, prompting the long-term Diabetes Prevention Program Outcomes Study (DPPOS) to assess the progression of diabetes and its complications over 22 years. During follow-up, departures from the original metformin or placebo assignment occurred primarily because of development of diabetes that, by protocol, was managed by clinicians outside the study, after participants developed diabetes with HbA1c ≥7.0%. Diabetes development led to changes in metformin treatment and addition of other glucose-lowering therapies. Using statistical methods designed to estimate intervention effects despite these deviations, we consistently found that metformin reduced diabetes incidence. However, using these methods to evaluate whether use of metformin for prediabetes confers continued benefits after diabetes diagnosis did not substantially change the conclusions from those of the simpler intention-to-treat analysis that did not account for treatment changes. All of the analytic methods used resulted in similar metformin effect estimates with 95% CIs for hazard ratios including 1.0 (no effect) for all outcomes except for diabetes incidence. Elucidating metformin's long-term role in mitigating diabetes-related complications beyond its effects on diabetes prevention is challenging.
引用
- Knowler WC, Pan Q, Shu S, et al. Analysis of Long-term Follow-up of a Randomized Clinical Trial With Departures From Assigned Treatments: Estimation of Metformin Effects on Diabetes and Its Complications in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2025. PMID: 40857175. doi:10.2337/dci25-0032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。